Prostate Clinic London

What Is Cascade Genetic Testing After a Familial Prostate Cancer Gene Result?

If your genetic test identifies an inherited cancer-risk variant, your biological relatives may carry it too. Cascade testing helps your family find out who has inherited the same variant.

If your relatives test positive, their doctor can explain their cancer risks and whether earlier screening is appropriate. If they test negative, they have not inherited the increased risk linked to that family variant. This can help you and your family make more informed decisions about your health.

What Exactly Is Cascade Genetic Testing?

Cascade genetic testing begins when your genetic test identifies a pathogenic or likely pathogenic inherited variant. Your biological relatives can then be offered targeted testing to find out whether they carry the same variant.

For example, if you carry a BRCA2 variant, your children, brothers and sisters may also be eligible for testing. If a relative tests positive, their children may be offered testing too. This helps your family understand their inherited cancer risks without everyone needing a broad genetic test.

How Does Cascade Testing Usually Work?

StepWhat happens
1. Variant identifiedA pathogenic or likely pathogenic germline variant is confirmed in one family member
2. Family is informedThe genetics team may provide a family letter or copy of the report
3. Close relatives consider testingParents, siblings and adult children may be offered targeted testing
4. Relative tests positiveGene-specific cancer-risk advice and surveillance may be discussed
5. Relative tests negativeThey have not inherited that familial variant
6. Testing extends through the familyIf appropriate, more distant relatives may then be offered predictive testing

Why Does Cascade Testing Only Follow a Confirmed Germline Result?

A genetic change found in your prostate tumour is not always inherited. Some changes develop only in cancer cells and cannot be passed to your children. These are called somatic variants.

If your tumour test identifies a change in BRCA2 or another risk gene, your doctor may recommend a blood or saliva test to check whether it is inherited. Cascade testing is usually considered when a pathogenic or likely pathogenic germline variant is confirmed, helping your family avoid unnecessary testing and uncertainty.

Who Is Usually Tested First in a Family?

Doctor talking with an older man in a clinic

If someone in your family already has prostate cancer, genetic testing usually starts with them. Their results can help identify an inherited risk variant that other family members may also carry.

If a pathogenic or likely pathogenic variant is found, your relatives can be tested for that specific familial variant. If your affected relative cannot be tested, a genetic counsellor can help you decide who might be tested instead and what the results could mean for your family.

Which Relatives May Be Offered Cascade Testing?

Cascade testing is usually offered to biological relatives who may have inherited the same familial genetic variant.

  • Biological children: For many autosomal-dominant inherited cancer-risk variants, each biological child generally has a 50% chance of inheriting the familial variant.
  • Brothers and sisters: Siblings may also have inherited the same variant from a shared parent.
  • Parents: Testing a parent can help show which side of the family the variant came from.
  • More distant relatives: Depending on the family pattern, relatives such as aunts, uncles or cousins may also be considered for testing.

A genetic counsellor can help identify which relatives are most likely to benefit from testing and personalised cancer-risk advice.

Does Every Relative Need to Be Tested at the Same Time?

No. If you carry an inherited cancer-risk variant, your family can usually arrange testing step by step. Your genetic counsellor can help decide which relatives should be tested first and which side of the family may be affected.

Your relatives do not all need testing immediately. For many prostate cancer-related genes, testing is most useful in adulthood, when the results can guide screening and risk management. Your genetics team can help your family decide on the right timing.

Evidence Note

Once a pathogenic familial variant is known, targeted predictive testing can answer a much narrower question: did this relative inherit the specific variant already identified in the family?

This avoids repeating broad gene panels in every relative and makes a negative result easier to interpret. In England, R242 is the NHS predictive-testing pathway for unaffected relatives when a familial pathogenic or likely pathogenic variant has already been identified.

What Happens If a Relative Tests Positive?

If your relative tests positive for the family variant, it does not mean they have cancer. It means they may have a higher chance of developing certain cancers, depending on the gene involved.

For you, the genetics team can explain what the result means for your relative, while their own clinical team can advise on appropriate surveillance or risk management. For example, a male BRCA2 carrier may need risk-based prostate assessment, depending on his age, family history and current screening eligibility. If they have a Lynch syndrome variant, screening for colorectal and other cancers may also be important. The aim is to help your family understand their risks and take suitable steps early.

What Happens If a Relative Tests Negative?

If your family has a known pathogenic familial variant and your test is negative for that specific variant, you have not inherited the additional cancer risk linked to it. You also cannot pass that particular variant to your children.

For example, if your father carries a BRCA2 variant and you test negative for it, you have not inherited his BRCA2-related risk. However, your age, family history and other risk factors can still affect your cancer risk, so your doctor can help you understand what screening is appropriate for you.

Does a Negative Cascade Test Remove All Prostate Cancer Risk?

Doctor talking with an older man in a clinic

No. If you test negative for your family’s known variant, you have not inherited the extra risk linked to that specific change. However, you can still develop prostate cancer due to factors such as age, ethnicity or other family history.

If you have other relatives with prostate cancer, tell your doctor even if your genetic test is negative. They can help you understand your remaining risk and whether prostate checks are appropriate for you.

How Does Cascade Testing Work for BRCA2 Families?

If you carry a pathogenic BRCA2 variant, your biological relatives may also carry it, so testing can be useful for both men and women. Men may have a higher risk of prostate cancer, while women may have increased risks of breast and ovarian cancer.

You can inherit BRCA2 from either your mother or father, and you can pass it on to your sons or daughters. Your genetic counsellor can help you understand which family members should consider testing and what their results could mean for their future health.

Research Insight

The 2026 UK National Screening Committee recommendation did more than endorse two-yearly PSA testing for a defined group of men with pathogenic germline BRCA2 variants. It also recommended evaluating the best methods of cascade identification so eligible male relatives can be found and invited into the targeted screening pathway.

This means cascade testing may have implications beyond family-risk counselling as the targeted screening programme is implemented. In some BRCA2 families, identifying a male relative who carries the familial variant may determine whether he meets the UK NSC criteria for the new targeted prostate-cancer screening programme.

How Is Cascade Testing Different for HOXB13?

If you carry a pathogenic HOXB13 variant, particularly G84E, your male relatives may benefit from testing and advice about their prostate cancer risk. Unlike BRCA2, HOXB13 is mainly linked to inherited prostate cancer susceptibility rather than a wider range of cancer risks or targeted treatment.

Your female relatives can also carry the variant and pass it on to their children. If your daughter inherits it, for example, she may pass it to her son. Your genetic counsellor can help your family understand who may benefit from testing and earlier prostate assessment.

How Does Cascade Testing Work in Lynch Syndrome Families?

If you carry a pathogenic Lynch syndrome-associated variant, your relatives may also benefit from genetic testing. This is important because Lynch syndrome can increase your risk of prostate, bowel, womb and other cancers.

If your brother tests positive, his clinical team can advise on gene-specific colorectal surveillance and whether prostate risk assessment is appropriate. Your sister or daughter may need guidance on bowel, womb and other cancer risks. Testing helps your family understand their risks and take steps towards earlier detection or prevention.

Who Tells Relatives About the Genetic Result?

If your genetic test identifies an inherited cancer-risk variant, you are usually encouraged to share the result with your relatives. This can feel difficult, but your genetics team may provide a family letter explaining what the result means and how relatives can arrange testing.

Your relatives can then decide whether they want testing. The aim is to help your family understand their risks and consider earlier screening or prevention, without pressuring anyone to find out their genetic status.

Clinical Tip

When a pathogenic variant is confirmed, ask the genetics team for a family letter or a copy of the relevant result that relatives can show to their GP or genetics service.

The document should identify the exact gene and variant. Saying only “BRCA runs in my family” is much less useful than providing the confirmed familial result, because predictive testing is designed to look for that specific change.

Can a Relative Choose Not to Have Cascade Testing?

Doctor talking with an older man in a clinic

Yes, genetic testing is your choice. You may want to understand your inherited cancer risk, while another family member may prefer not to know. Your genetics team can explain what the results could mean and whether testing could help guide screening or prevention.

The benefits also depend on the gene involved. For example, a BRCA2 result may offer clearer guidance than a less well-understood variant. The aim is to help you make an informed decision without feeling pressured to have testing.

Can Cascade Testing Be Offered to Children?

If you carry an inherited cancer-risk variant, your children may not need testing immediately. For genes such as BRCA2 and HOXB13, the relevant cancer risks mainly arise in adulthood, so predictive testing is generally deferred until the result can affect care and the person can make an informed decision.

If a genetic condition could affect your child’s health during childhood, earlier testing may be helpful. Your genetics team can guide you on when testing makes sense for your family, so you can focus on what your children need and when they need it.

Does Cascade Testing Affect Prostate Cancer Screening?

Yes. If you carry a pathogenic germline BRCA2 variant, your doctor may recommend earlier prostate checks based on your age and family history. In 2026, the UK National Screening Committee recommended targeted screening every two years for certain men aged 45–61 with a BRCA2 variant and a relevant family history.

If you test positive for a family variant, you can discuss whether earlier PSA testing is right for you. If you test negative, you have not inherited the risk linked to that specific variant. For genes such as HOXB13, your doctor can help you decide when prostate checks may be appropriate.

UK Guidance Note

The UK National Screening Committee specifically highlighted the need to develop effective cascade identification of germline BRCA2 carriers so that eligible men can be proactively invited into the new targeted PSA-screening programme.

For the recommended programme, eligibility is narrow: men must be aged 45–61, have a pathogenic germline BRCA2 variant and have the specified relevant family history. Men with BRCA1 alone, family history alone, Black ethnicity alone or another prostate-cancer susceptibility gene are not currently included in the national targeted programme.

How Is Cascade Testing Arranged in the NHS?

Doctor at a desk talking with an older man

If your genetic test identifies an inherited cancer-risk variant, your genetics team can explain how your relatives can arrange testing through the NHS. The process depends on the gene involved, your family history and local services. Your relatives may need a report confirming the exact variant found in your results.

If you receive a pathogenic germline result privately, ask how your family can access NHS genetics services and which relatives should consider testing first. For you, this helps clarify who may carry the variant and what the result could mean for future care.

Myth vs Fact

MythFact
Cascade testing means every relative gets a full genetic panel.Usually relatives are tested specifically for the known familial variant.
A tumour BRCA result can immediately be used for family testing.Germline origin needs to be confirmed first.
A VUS should be tested across the family.A VUS is not clinically actionable and is not normally used for predictive cascade testing.
Every child of a BRCA2 carrier will inherit the variant.Each child generally has a 50% chance.
A positive cascade test means cancer is present.It indicates inherited risk, not a cancer diagnosis.
A negative cascade test means there is no prostate-cancer risk.It removes the risk from that familial variant, not all background risk.
HOXB13 carriers automatically enter the new UK prostate-screening programme.The programme currently applies to a defined BRCA2 group only.
All Lynch carriers have the same cancer risks.Risk and surveillance differ by the mismatch-repair gene involved.
Children should always be tested immediately.Adult-onset cancer-risk testing is generally deferred until the result can affect care and informed consent is possible.
The NHS automatically contacts every relative.Families are usually supported to share the result and relatives then access genetics services.

Key Takeaways

  • Cascade testing follows a confirmed pathogenic or likely pathogenic germline variant.
  • In the NHS, predictive testing for a known familial variant is covered by R242.
  • Relatives usually have targeted testing for the exact familial variant, not a repeat broad gene panel.
  • Tumour-only somatic variants should not automatically trigger family cascade testing.
  • A VUS is not clinically actionable and should not normally be used for predictive testing.
  • Parents, siblings and adult children are often the first relatives considered.
  • For many autosomal-dominant hereditary cancer variants, each child has about a 50% chance of inheriting the variant.
  • A positive result means inherited risk, not a cancer diagnosis.
  • A true negative means the relative has not inherited that specific familial variant.

Frequently Asked Questions

1. What is cascade genetic testing for prostate cancer?
Cascade genetic testing is a process in which biological relatives are offered genetic testing after a family member is found to carry an inherited cancer-risk variant. It helps identify relatives who may benefit from personalised cancer-risk advice and screening.

2. Who should have genetic testing first in a family?
Genetic testing usually starts with a family member who has prostate cancer, particularly if they have a strong family history or other features suggesting inherited risk. If a pathogenic or likely pathogenic germline variant is identified, relatives can be offered targeted testing for the same familial variant.

3. Which family members should consider cascade genetic testing?
Biological children, parents, brothers and sisters may be eligible for cascade testing, depending on the gene involved and family history. More distant relatives may also benefit if the variant has been passed through several generations.

4. What happens if a relative tests positive for an inherited prostate cancer risk variant?
A positive result means the relative carries the identified variant, which may increase their risk of certain cancers. Their doctor or genetic counsellor can explain their individual risk and recommend appropriate screening or risk-management options.

5. What happens if a relative tests negative for the family variant?
If a relative tests negative for a known familial variant, they have not inherited the increased risk associated with that specific variant. However, their age, other family history and additional risk factors may still influence their cancer risk.

6. Does a negative cascade genetic test mean there is no risk of prostate cancer?
No. A negative result for a known family variant removes the inherited risk associated with that specific change, but it does not eliminate the general risk of prostate cancer. Your doctor can advise whether screening is appropriate based on your personal and family history.

7. How does cascade testing work for BRCA2 and HOXB13 variants?
For BRCA2, cascade testing can help identify relatives who may have increased risks of prostate, breast and ovarian cancers. HOXB13 variants, particularly G84E, are mainly associated with inherited prostate cancer susceptibility. Testing can help families understand which relatives may benefit from risk assessment.

8. Can family members choose not to have cascade genetic testing?
Yes. Genetic testing is a personal choice, and relatives can decide whether they want to know their genetic status. A genetic counsellor can explain the potential benefits and limitations of testing without pressuring anyone to participate.

9. Can children have cascade genetic testing for inherited prostate cancer risk genes?
For genes such as BRCA2 and HOXB13, predictive testing is generally considered when the result can affect care and the person can participate in an informed decision, because the associated cancer risks mainly arise in adulthood. A genetics specialist can advise on the appropriate timing for each family.

10. How does cascade genetic testing affect prostate cancer screening?
If testing identifies an inherited risk variant, a doctor may recommend earlier or more personalised prostate cancer assessment, depending on the gene, age and family history. A genetic counsellor can explain whether PSA testing or other screening options are appropriate.

Final Thoughts: Cascade Genetic Testing and Prostate Cancer

Cascade genetic testing can help identify family members who have inherited a prostate cancer-related gene variant, allowing them to understand their individual cancer risks and consider appropriate screening. Whether the result involves BRCA2, HOXB13 or a Lynch syndrome gene, genetic counselling can help your family understand the results and make informed decisions about testing and future care.

If you would like specialist advice about inherited prostate cancer risk or genetic testing, you can contact Prostate Clinic London to discuss whether further assessment may be appropriate for you.

References:

  1. NHS England Genomics Education Programme (no date) BRCA1 and BRCA2-associated cancer risk. GeNotes. Available at:
    https://www.genomicseducation.hee.nhs.uk/genotes/knowledge-hub/brca1-and-brca2/
  2. NHS England Genomics Education Programme (no date) Variant of uncertain significance (VUS). GeNotes. Available at:
    https://www.genomicseducation.hee.nhs.uk/genotes/knowledge-hub/variant-of-uncertain-significance-vus/
  3. NHS (no date) Genetic tests to check your cancer risk. Available at:
    https://www.nhs.uk/tests-and-treatments/genetic-tests-for-cancer-risk/
  4. NHS England Genomics Education Programme (no date) ‘Predictive testing’. GeNotes. Available at: https://www.genomicseducation.hee.nhs.uk/genotes/knowledge-hub/predictive-testing/
  5. UK National Screening Committee (2026) ‘UK NSC minutes March 2026’. Available at: https://www.gov.uk/government/publications/uk-nsc-meeting-march-2026/uk-nsc-draft-minutes-march-2026
  6. NHS England (2026) National Genomic Test Directory. Available at:
    https://www.england.nhs.uk/publication/national-genomic-test-directories/